

AD No.	Amendment No.	Federal Register citation	Date of publication	name: inter
89-07-15	39-6167	54 FR 11693	March 22, 1989.	
87-04-13 R1	39-5546	52 FR 3421	February 4, 1987.	
86-08-03	39-5289	51 FR 12836	April 16, 1986.	
86-07-06	39-5270	51 FR 10821	March 31, 1986.	
86-05-11	39-5255	51 FR 8479	March 12, 1986.	
86-23-01	39-5450	51 FR 37712	October 24, 1986.	
82-22-02	39-4476	47 FR 46842	October 21, 1982.	
80-08-02	39-3738	45 FR 24450	April 10, 1980.	
79-17-07	39-3533	44 FR 50033	August 27, 1979.	

(d) An alternative method of compliance or adjustment of the compliance time that provides an acceptable level of safety may be used if approved by the Manager, Seattle ACO. Operators shall submit their requests through an appropriate FAA Principal Maintenance Inspector, who may add comments and then send it to the Manager, Seattle Aircraft Certification Office (ACO), FAA, Transport Airplane Directorate.

Note 7: Information concerning the existence of approved alternative methods of compliance with this AD, if any, may be obtained from the Seattle ACO.

(e) Special flight permits may be issued in accordance with sections 21.197 and 21.199 of the Federal Aviation Regulations (14 CFR 21.197 and 21.199) to operate the airplane to a location where the requirements of this AD can be accomplished.

Issued in Renton, Washington, on December 15, 1994.

S.R. Miller,

Acting Manager, Transport Airplane Directorate, Aircraft Certification Service.

[FR Doc. 94-31328 Filed 12-20-94; 8:45 am]

BILLING CODE 4910-13-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Chapter I

[Docket No. 88N-0004]

Pediatric Dosing with Over-the-Counter Drug Products; Summary Information Document for Advisory Committee Meeting; Availability; Establishment of a Public Docket and Request for Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Availability of summary information document; establishment of a public docket and request for comments.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a summary information

document for the Nonprescription Drugs Advisory Committee meeting on pediatric dosing with over-the-counter (OTC) drug products. Elsewhere in this issue of the **Federal Register**, the agency is announcing a forthcoming meeting of this advisory committee. The action is being taken to ensure that all interested parties are aware of the issues that are the subject of the committee discussion. FDA is also announcing that it has established a public docket for comments, views, and other information submitted to the agency on these subjects from interested persons.

DATES: Submit written comments by March 14, 1994. Comments received before the January 13, 1995, advisory committee meeting will be distributed to the committee as soon as possible.

ADDRESSES: Submit written comments or relevant data and requests for single copies of the summary information document to the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857.

Comments and requests should be identified with the docket number found in brackets in the heading of this document. Send two self-addressed adhesive labels to assist the branch in processing your requests. Please note that copying charges may be assessed. Three copies of written comments should be submitted, except that individuals may submit one copy. The summary information document and received comments are available for public examination at the Dockets Management Branch (address above), between 9 a.m. and 4 p.m., Monday through Friday.

FOR FURTHER INFORMATION CONTACT: Lee L. Zwanziger or Liz Ortuzar, Center for Drug Evaluation and Research (HFD-9), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5455.

SUPPLEMENTARY INFORMATION: Elsewhere in this issue of the **Federal Register**,

FDA is announcing a forthcoming meeting of the Nonprescription Drugs Advisory Committee on pediatric dosing (use by children under 12 years of age) of OTC drug products. FDA is holding this meeting to discuss topics such as:

(1) What is the most preferred and practical basis for determining and labeling OTC systemic pediatric dosages, e.g., age, weight, height (length), body surface area, or a combination of these?

(2) Is the dosing approach (adult-1 full dose, children 6 to 12-1/2 adult dose, and children 2 to 6-1/4 adult dose) currently being used for most OTC oral drugs an adequate method of dosing?

(3) Should there be differences in systemic pediatric dosing ranges for specific ingredients or different classes of OTC drug products? If yes, for which specific ingredients or classes of products?

(4) Should calibrated dosage devices be required for (specific or all) pediatric products? If yes, for which product(s) and how should they be calibrated (e.g., devices expressing dosage levels in teaspoon or milliliter units)?

(5) What are the lowest limits (e.g., age, weight, etc.) for which specific dosing instructions should appear in OTC product labeling? Would these limits be different for certain classes of OTC drugs, such as internal analgesics, antihistamines, etc.?

The purpose of this meeting is to address specific topics and questions contained in the summary information document that could result in future rulemaking. FDA has established public docket no. 88N-0004 to enable interested persons to submit comments or other relevant data on the summary information document.

Dated: December 14, 1994.

Linda A. Suydam,
Interim Deputy Commissioner for Operations
[FR Doc. 94-31297 Filed 12-20-94; 8:45 am]
BILLING CODE 4160-01-F

Trust Company, Arkadelphia, Arkansas; and Grant County Bank, Sheridan, Arkansas.

C. Federal Reserve Bank of Minneapolis (James M. Lyon, Vice President) 250 Marquette Avenue, Minneapolis, Minnesota 55480:

1. *Kootenai Bancorp, Inc.*, Libby, Montana; to acquire 100 percent of the voting shares of First National Bank of Montana, Butte, Montana.

2. *Winton Jones Limited Partnership and Anchor Bancorp, Inc.*, both of Wayzata, Minnesota; to acquire 100 percent of the voting shares of First National Bank of Farmington, Farmington, Minnesota.

D. Federal Reserve Bank of Kansas City (John E. Yorke, Senior Vice President) 925 Grand Avenue, Kansas City, Missouri 64198:

1. *Citizens National Corporation*, Wisner, Nebraska; to acquire 100 percent of the voting shares of The First National Bank of Attica, Attica, Kansas. **Comments must be received by January 10, 1995.**

2. *Hoeme Family Partnership*, Scott City, Kansas; to become a bank holding company by acquiring 33.50 percent of the voting shares of First National Bancshares of Scott City, Ltd., Scott City, Kansas, and thereby indirectly acquire The First National Bank of Scott City, Scott City, Kansas.

3. *Union Bancshares, Inc.*, Wichita, Kansas; to acquire 100 percent of the voting shares of CBI-Central Kansas, Inc., Kansas City, Missouri, and thereby indirectly acquire Commerce Bank, N.A., Manhattan, Kansas; Commerce Bank, N.A., Hays, Kansas; and Commerce Bank, El Dorado, Kansas. **Comments should be received not later than January 4, 1995.**

E. Federal Reserve Bank of Dallas (Genie D. Short, Vice President) 2200 North Pearl Street, Dallas, Texas 75201-2272:

1. *Nacogdoches Commercial Bancshares, Inc.*, Nacogdoches, Texas; to acquire 100 percent of the voting shares of Security National Bank, Nacogdoches, Texas.

Board of Governors of the Federal Reserve System, December 15, 1994

Jennifer J. Johnson,

Deputy Secretary of the Board

[FR Doc. 94-31303 Filed 12-20-94 8:45 am]

BILLING CODE 6210-01-F

GENERAL ACCOUNTING OFFICE

Federal Accounting Standards Advisory Board

AGENCY: General Accounting Office.

ACTION: Notice of Public Hearing.

SUMMARY: Pursuant to section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), as amended, notice is hereby given that a two-day public hearing of the Federal Accounting Standards Advisory Board will be held on January 9, and 10, 1995 from 9:00 a.m. to 4:30 p.m. in room 4N30 (not 7C13) of the General Accounting Office, 441 G St., NW., Washington, DC.

The purpose of the hearing is to hear testimony from interested parties on the recently issued Accounting for Liabilities of the Federal Government and Managerial Cost Accounting Standards exposure drafts (ED's).

Those interested in testifying should contact the Executive Director by December 31. Presenters should provide a written outline of their comments to the Board prior to the hearing.

Any interested person may attend the hearing as an observer. Board discussions and reviews are open to the public.

FOR FURTHER INFORMATION CONTACT: Ronald S. Young, Executive Staff Director, 750 First St., NE., room 1001, Washington, DC 20002, or call (202) 512-7350.

Authority: Federal Advisory Committee Act, Pub. L. 92-463, Section 10(a)(2), 86 Stat. 770, 774 (1972) (current version at 5 U.S.C. app. section 10(a)(2) (1988)); 41 CFR 101-6.1015 (1990).

Dated: December 16, 1994.

Ronald S. Young,

Executive Director

[FR Doc. 94-31347 Filed 12-20-94; 8:45 am]

BILLING CODE 1610-01-M

Federal Accounting Standards Advisory Board

AGENCY: General Accounting Office.

ACTION: Notice of meeting.

SUMMARY: Pursuant to section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), as amended, notice is hereby given that the regular monthly meeting of the Federal Accounting Standards Advisory Board will be held on January 18 from 10:00 A.M. to 4:00 P.M. and January 19 from 9:00 A.M. to 4:30 P.M., in room 7C13 of the General Accounting Office, 441 G St., N.W. Washington, D.C.

The agenda for the meeting includes discussions of (1) the draft Exposure Draft on *Stewardship Reporting*, (2) review of the draft of the Recommended Statement on *Entity and Display*, (3) the *Revenue Recognition* draft Exposure Draft, and (4) the *Property, Plant and Equipment* Exposure Draft.

We advise that other items may be added to the agenda; interested parties should contact the Staff Director for more specific information and to confirm the date of the meeting. Any interested person may attend the meeting as an observer. Board discussions and reviews are open to the public.

FOR FURTHER INFORMATION CONTACT: Ronald S. Young, Executive Staff Director, 750 First St., N.E., Room 1001, Washington, D.C. 20002, or call (202) 512-7350.

Authority: Federal Advisory Committee Act, Pub. L. 92-463, Section 10(a)(2), 86 Stat. 770, 774 (1972) (current version at 5 U.S.C. app. section 10(a)(2) (1988)); 41 CFR 101-6.1015 (1990).

Dated: December 16, 1994.

Ronald S. Young,

Executive Director

[FR Doc. 94-31348 Filed 12-20-94; 8:45 am]

BILLING CODE 1610-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 92N-0457]

Arnold S. Mendell; Debarment Order

AGENCY: Food and Drug Administration HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (the act) permanently debarbing Mr. Arnold S. Mendell, 500 Peconic St., Ronkonkoma, NY 11779 from providing services in any capacity to a person that has an approved or pending drug product application. FDA bases this order on a finding that Mr. Mendell was convicted of a felony under Federal law for conduct relating to the regulation of a drug product under the act. Mr. Mendell has failed to file with FDA information and analyses sufficient to create a basis for a hearing concerning this action.

EFFECTIVE DATE: December 21, 1994

ADDRESSES: Application for termination of debarment to the Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857

FOR FURTHER INFORMATION CONTACT: Tamar S. Nordenberg, Center for Drug Evaluation and Research (HFD-366), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-594-2041